GlassScriptPhysician profile
Geraldo A Ramos
NPI 1881845543
$116,546.93
in general payments reported to CMS, 2019-2025
29 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $28K · 2021: $21K · 2022: $15K · 2023: $11K · 2024: $15K · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Honoraria: $6,955 · Food and Beverage: $5,529 · Education: $31.51 · Travel and Lodging: $13.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,290.00 |
| Honoraria | $6,955.00 |
| Food and Beverage | $5,529.05 |
| Education | $31.51 |
| Travel and Lodging | $13.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50,832.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $34,662.15 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Lilly USA, LLC | $16,509.08 | 2019-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $7,491.85 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $800.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $696.33 | 2019-2024 | Xarelto |
| Amgen INC. | $633.69 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $605.06 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $555.41 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $530.82 | 2019-2025 | |
| Boston Scientific Corporation | $380.97 | 2021-2025 | Watchman Access System, General - Crm_crm, Acuity Steerable |
| Bayer Healthcare Pharmaceuticals INC. | $340.08 | 2021-2025 | |
| Amarin Pharma, INC. | $323.93 | 2019-2021 | |
| Pfizer INC. | $305.40 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $264.72 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $258.64 | 2024-2025 | |
| Nuwellis, INC. | $252.21 | 2019-2025 | Aquadex Smartflow Console |
| Abbott Laboratories | $227.79 | 2021-2024 | Aveir |
| Esperion Therapeutics, INC. | $186.99 | 2020-2025 | Nexletol |
| Medtronic Vascular, INC. | $180.35 | 2019 | |
| Abiomed | $119.32 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.81 | 2019-2025 | Lifevest |
| Abbvie INC. | $102.24 | 2021 | |
| Medtronic, INC. | $57.57 | 2021 | |
| Alnylam Pharmaceuticals INC. | $53.15 | 2024-2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $18.54 | 2019 | |
| Preventice Services, LLC | $17.63 | 2021 | |
| Ge Healthcare | $16.73 | 2020 | |
| Cvrx, INC. | $9.23 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldo Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.